Aspire Biopharma Holdings, Inc.
ASBP
$1.06
-$0.14-11.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.71M | -1.85M | -1.98M | -15.94M | -765.70K |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 6.00M | 2.02M | -- | -- | -- |
| Total Other Non-Cash Items | -3.10M | -1.59M | 1.18M | 14.52M | -- |
| Change in Net Operating Assets | 881.70K | 318.40K | -340.40K | -326.30K | 1.25M |
| Cash from Operations | -927.80K | -1.10M | -1.14M | -1.75M | 479.60K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 0.00 | 7.25M | 0.00 | 3.05M | -492.50K |
| Total Debt Repaid | -16.50K | -3.50M | 0.00 | -221.40K | -- |
| Issuance of Common Stock | 545.50K | -- | 265.80K | -- | 0.00 |
| Repurchase of Common Stock | -- | 0.00 | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -545.50K | -907.50K | -265.80K | 265.80K | -- |
| Cash from Financing | -16.50K | 2.85M | 0.00 | 3.09M | -492.50K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -944.40K | 1.74M | -1.14M | 1.34M | -12.90K |